Coronary Stents Market Size, Share, and Growth Forecast 2026 - 2033

The global coronary stents market is expected to be valued at US$ 10.4 billion in 2026 and is projected to reach US$ 16.1 billion, growing at a CAGR of 6.4% between 2026 and 2033.

Market growth is primarily driven by the rising prevalence of coronary artery disease (CAD), increasing incidence of myocardial infarction, and growing adoption of minimally invasive percutaneous coronary intervention (PCI) procedures. Coronary stents are widely used to restore blood flow in narrowed or blocked coronary arteries, reducing ischemic symptoms and supporting improved patient outcomes. Technological advancements, particularly in drug-eluting stents featuring thinner struts and advanced polymer coatings, continue to enhance procedural performance and long-term clinical outcomes.

Drivers - Rising Global Burden of Coronary Artery Disease

Cardiovascular disease remains the leading contributor to global mortality, with the World Health Organization (WHO) estimating that cardiovascular diseases account for around 17.9 million deaths annually, with ischemic heart disease representing a substantial share of this burden. The Centers for Disease Control and Prevention (CDC) reports that someone in the U.S. experiences a heart attack approximately every 40 seconds, underscoring the continued need for timely coronary revascularization and associated interventional procedures.

Aging populations, rising prevalence of diabetes and hypertension, and increasing urbanization-linked lifestyle risk factors are compounding this burden across both developed and emerging economies. The American Heart Association (AHA) anticipates that the population burden of cardiovascular disease will continue increasing over the coming decade, a trend that supports sustained demand for coronary intervention and stent implantation procedures across hospital and catheterization laboratory settings worldwide.

Technological Advancement in Drug-Eluting and Bioresorbable Platforms

Continuous innovation in stent design, including ultra-thin cobalt-chromium and platinum-chromium alloy platforms coated with durable or bioresorbable polymers, is improving device performance and expanding physician confidence in treatment selection. Clinical trial data published in peer-reviewed cardiology journals have demonstrated lower target lesion revascularization rates with newer-generation drug-eluting stents compared with earlier bare-metal designs, reinforcing their widespread adoption across appropriate lesion types.

Regulatory clearances from the U.S. Food and Drug Administration (FDA) and approvals under the European Union's Medical Device Regulation (MDR) are supporting commercial rollout of next-generation stent platforms across major markets. Companies such as Abbott Laboratories and Boston Scientific Corporation continue to invest in strut-thickness reduction, polymer technology, and drug-elution kinetics, a competitive dynamic that is steadily advancing clinical performance across the coronary stents category and expanding treatment options for complex coronary lesions.

Restraints - Pricing Pressure from Government Procurement and Reimbursement Policies

Coronary stent pricing has come under sustained downward pressure following centralized procurement initiatives such as China's volume-based procurement (VBP) program, which has significantly compressed prices for selected tender-winning medical devices. Similar cost-containment measures administered through India's National Pharmaceutical Pricing Authority (NPPA), which regulates coronary stent prices under India's drug price control framework, have narrowed manufacturer margins in one of the world's major PCI markets.

These policy interventions, while improving patient affordability and access, compel device manufacturers to pursue manufacturing efficiencies and volume-based commercial strategies. Smaller manufacturers with limited economies of scale face particular difficulty sustaining profitability under compressed pricing environments, which can favor larger device companies with broader manufacturing capabilities and established distribution networks.

Risk of Stent Thrombosis and Long-Term Restenosis Complications

Despite considerable design improvements, coronary stent implantation continues to carry residual clinical risks, including stent thrombosis and in-stent restenosis, which can necessitate repeat revascularization procedures. Data from clinical studies and cardiology registries indicate that contemporary drug-eluting stents continue to carry a measurable risk of target lesion failure, reinforcing the importance of appropriate patient selection, procedural technique, and post-procedural management.

Dual antiplatelet therapy is routinely used following PCI, with treatment duration individualized according to ischemic and bleeding risks and recommendations from organizations such as the American College of Cardiology (ACC) and European Society of Cardiology (ESC). Bleeding considerations are particularly relevant for elderly and comorbid patients, complicating post-procedural treatment decisions. Persistent clinical attention to device-related complications continues to influence treatment selection in certain patient populations, tempering unrestricted stent adoption despite favorable procedural volume trends across major healthcare systems.

Opportunities - Commercial Expansion of Bioresorbable Vascular Scaffold Technology

Bioresorbable vascular scaffolds, designed to provide temporary vessel support before gradually resorbing, represent an important innovation area within the coronary stents category. Following the clinical setbacks associated with some first-generation bioresorbable platforms, manufacturers have focused on thinner struts, improved mechanical characteristics, and more favorable deployment profiles aimed at addressing earlier safety and performance concerns. Regulatory and clinical evaluation of newer scaffold technologies continues as additional evidence becomes available.

As scaffold designs and procedural techniques advance, bioresorbable platforms have potential to gain adoption in selected patient populations, particularly younger patients for whom the long-term presence of a permanent metallic implant is a consideration. Continued investment in scaffold technology therefore presents a long-term opportunity for manufacturers seeking to differentiate within the coronary intervention market.

Expansion of Cardiac Catheterization Infrastructure Across Emerging Markets

Government-backed investment in tertiary cardiac care infrastructure across Asia Pacific and Latin America is creating substantial headroom for coronary stent volume growth beyond mature Western markets. India's Ayushman Bharat health insurance initiatives have expanded access to cardiovascular procedures for eligible populations, while China's expanding network of tertiary cardiovascular centers continues to strengthen catheterization capacity across provincial hospital systems.

Manufacturers including MicroPort Scientific Corporation and Meril Life Sciences Pvt. Ltd. have established regional manufacturing and distribution capabilities positioned to serve this expanding procedural base. As catheterization laboratory availability increases across secondary cities in emerging economies, device companies with established local regulatory approvals, manufacturing capabilities, and distribution relationships are positioned to capture incremental procedural demand over the forecast period.

Product Type Insights

Drug-eluting stents (DES) represent the leading segment, accounting for around 38% share of the coronary stents market in 2026, owing to their lower restenosis rates and strong clinical performance compared with bare-metal alternatives.

Data from the American College of Cardiology (ACC)'s National Cardiovascular Data Registry indicates that drug-eluting platforms are used in the substantial majority of contemporary percutaneous coronary intervention procedures across major healthcare systems. Continuous innovation in polymer coating chemistry, drug-delivery systems, and stent design has further improved clinical performance while supporting broader adoption across different lesion types.

Leading manufacturers, including Boston Scientific Corporation and Abbott Laboratories, continue to invest in thinner struts and advanced drug-elution technologies, reinforcing the competitive position of DES. As clinical guidelines from organizations such as the American Heart Association (AHA) and European Society of Cardiology (ESC) continue to favor drug-eluting platforms for most appropriate PCI procedures, DES is expected to retain its category leadership through the forecast period.

Bioresorbable vascular scaffolds (BVS)/bioabsorbable stents represent the fastest-growing product type segment, driven by continued technological improvements aimed at addressing the safety and performance limitations associated with earlier-generation devices.

Advances in scaffold design, thinner struts, improved radial strength, and more controlled resorption profiles are increasing clinical interest in temporary vessel-support technologies. Although adoption remains limited compared with established drug-eluting stents, continued research and development and growing interest in reducing the long-term presence of permanent metallic implants are expected to support segment expansion through the forecast period.

Material Insights

Cobalt-chromium represents the leading material segment, reflecting its favorable combination of high radial strength, thin strut profile, and biocompatibility, which has made it a widely used platform material for contemporary drug-eluting stent designs. Its strong strength-to-thickness ratio compared with earlier stainless steel platforms allows manufacturers to develop thinner struts while maintaining adequate vessel support. Thinner strut designs are associated with improved deliverability and favorable clinical outcomes, further supporting the use of cobalt-chromium across modern coronary stent platforms.

Leading manufacturers, including Biotronik and Terumo Corporation, have developed multiple stent product lines using cobalt-chromium platforms, reinforcing the material's established position across premium and value-oriented device segments. As next-generation stent designs continue prioritizing thinner struts, improved flexibility, and enhanced deliverability, the favorable mechanical properties of cobalt-chromium are expected to sustain its leading position across a substantial share of coronary stent designs through the forecast period.

Indication Insights

Coronary artery disease (CAD) represents the leading indication segment, reflecting its position as the primary underlying condition treated through a substantial share of percutaneous coronary intervention procedures globally. The World Health Organization (WHO) identifies ischemic heart disease as the leading cause of death worldwide, supporting sustained demand for coronary revascularization across elective and urgent care settings.

CAD-related stenting covers a broad range of disease presentations, including stable coronary lesions, progressive disease, and acute coronary syndromes requiring urgent intervention. This broad clinical application, combined with the continued use of PCI across hospital-based cardiac catheterization laboratories, supports CAD's position as the dominant indication driving overall coronary stent procedural volume across developed and emerging healthcare markets.

End-User Insights

Hospitals are expected to lead the coronary stents market while holding the largest share in 2026, supported by their comprehensive infrastructure for performing percutaneous coronary intervention and managing complex cardiovascular cases. Hospital-based cardiac catheterization laboratories provide access to emergency care, intensive care units, cardiac surgery support, advanced imaging, and specialized cardiology teams, making them particularly important for high-risk and acute presentations such as ST-elevation myocardial infarction.

Hospitals also benefit from established referral networks, emergency medical services connections, and round-the-clock clinical staffing, supporting rapid intervention for time-sensitive cardiac events. Although ambulatory surgical centers are gaining traction for selected elective and lower-risk cardiovascular procedures, hospitals continue to perform the majority of coronary stent procedures due to their broader case-mix capabilities and ability to manage complications requiring advanced cardiac care.

North America Coronary Stents Market Trends and Insights

North America is expected to maintain its leadership in the global coronary stents market by holding about 37% share in 2026. The region’s leadership is supported by high procedural volumes, established reimbursement pathways through the Centers for Medicare & Medicaid Services (CMS), and continued adoption of next-generation drug-eluting stent technologies across the region's extensive network of hospital-based and ambulatory cardiac catheterization laboratories.

The American College of Cardiology (ACC)'s National Cardiovascular Data Registry continues to document substantial percutaneous coronary intervention volumes across the U.S., reflecting a mature but sustained demand base. Growing adoption of same-day discharge protocols following selected elective PCI procedures, alongside expanding ambulatory surgical center capabilities for appropriate coronary interventions, is gradually diversifying the site-of-care mix while sustaining overall device demand across hospital and outpatient settings.

U.S. Coronary Stents Market Size

The U.S. is projected to hold a major share of the North American coronary stents market in 2026, supported by its extensive hospital and cardiac catheterization laboratory network and high volume of PCI procedures. Continued reimbursement support from the Centers for Medicare & Medicaid Services (CMS), combined with rapid clinical adoption of newer-generation drug-eluting stent platforms cleared by the U.S. Food and Drug Administration (FDA), continues to sustain device demand.

Expanding same-day discharge protocols and growing use of ambulatory surgical centers for selected lower-risk coronary interventions are gradually broadening the addressable site-of-care base, reinforcing the country's position as the largest national market in North America.

Europe Coronary Stents Market Trends and Insights

Europe's coronary stents market is influenced by regulatory oversight under the European Union's Medical Device Regulation (MDR), which has strengthened clinical evidence requirements and patient safety standards for new medical device technologies. Publicly funded healthcare systems across the region continue to emphasize cost-effective drug-eluting stent adoption, with clinical guidance from the European Society of Cardiology (ESC) informing procedural practices across national cardiology societies.

Increasing use of cardiac registries and standardized clinical outcome tracking is supporting evidence-based evaluation of newer stent technologies across Western and Central European markets. At the same time, healthcare procurement bodies continue to evaluate the clinical and economic value of premium stent platforms before expanding their use.

Germany Coronary Stents Market Size

Germany leads the European coronary stents market, supported by high PCI procedural volumes, a well-established network of cardiac catheterization laboratories, and comprehensive coverage through the country's statutory health insurance system. Continued investment in advanced cardiac imaging, catheterization laboratories, and specialized cardiovascular facilities is supporting the adoption of next-generation stent platforms. Germany's strong medical technology manufacturing base, including established cardiovascular device developers and suppliers, further strengthens its position as both a major consumption market and an important regional hub for coronary stent technology.

U.K. Coronary Stents Market Size

The U.K. is anticipated to hold a significant share of the European coronary stents market in 2026, supported by the National Health Service (NHS)'s structured monitoring of PCI procedures through the British Cardiovascular Intervention Society (BCIS). Continued NHS investment in reducing elective care backlogs and strengthening cardiovascular services is supporting recovery and expansion of PCI volumes. National Institute for Health and Care Excellence (NICE) guidance on the clinical and economic value of coronary stent technologies also influences procurement decisions, supporting continued adoption of clinically validated drug-eluting stents across the country's cardiac catheterization network.

France Coronary Stents Market Size

France is projected to hold a considerable share of the European market in 2026, supported by a well-developed network of cardiac catheterization centers and a comprehensive public healthcare system. Reimbursement oversight and health technology assessment through the Haute Autorité de Santé support the evaluation of new medical device technologies for inclusion within the reimbursable healthcare system. Continued investment in regional cardiology infrastructure is expanding access to PCI beyond major metropolitan areas, while collaboration between French university hospitals and international medical device manufacturers supports the clinical evaluation and adoption of next-generation stent platforms.

Asia Pacific Coronary Stents Market Trends and Insights

Asia Pacific represents the fastest-growing market through the forecast period, driven by expanding cardiac catheterization infrastructure, rising cardiovascular disease prevalence, urbanization, and increasing investment in tertiary cardiac care. China and India represent major contributors to regional growth as governments and healthcare providers expand access to cardiovascular diagnosis and intervention.

China's coronary stents market continues to be influenced by the country's volume-based procurement program, which has significantly reduced device prices while supporting broader affordability and access. At the same time, continued expansion of provincial cardiac centers and PCI capabilities is supporting growth in procedural volumes across the country.

India Coronary Stents Market Size

India represents one of the fastest-growing markets within Asia Pacific, supported by expanding healthcare infrastructure, broader coverage under government health insurance initiatives, and increasing access to PCI procedures across underserved populations. Government-backed healthcare programs, including Ayushman Bharat, are improving access to cardiovascular treatment for eligible patients, while expansion of cardiac catheterization laboratories across tier-two and tier-three cities is broadening the country's procedural base.

Domestic manufacturers such as Meril Life Sciences Pvt. Ltd. and Sahajanand Medical Technologies are strengthening their positions in the price-sensitive market through locally manufactured and competitively priced coronary stent platforms. Increasing cardiovascular disease awareness, improving diagnostic access, and continued investment in cardiac care infrastructure are expected to sustain strong demand through the forecast period.

The global coronary stents market is highly competitive, with established multinational manufacturers competing through continuous product innovation, clinical evidence, geographic expansion, and physician engagement. Market leaders focus on developing next-generation drug-eluting stents with thinner struts, advanced polymer coatings, and enhanced deliverability to improve long-term patient outcomes.

Companies are also investing in bioresorbable scaffold technologies and expanding manufacturing capabilities to meet growing demand in emerging markets. Strategic collaborations with hospitals, distributors, and research institutions, along with regulatory approvals and product launches, remain key competitive strategies.

Key Industry Developments

• In March 2026, Abbott Laboratories launched XIENCE Skypoint, its latest-generation everolimus drug-eluting coronary stent, in India. The stent is designed for complex percutaneous coronary interventions (PCI), offering enhanced flexibility, improved deliverability, and the broadest size range in the XIENCE portfolio, including indications for coronary vessels up to 5.25 mm to support the treatment of complex and large-vessel lesions
• In August 2025, a subgroup analysis from the AGENT IDE trial demonstrated that paclitaxel-coated drug-coated balloons (DCBs) effectively reduce restenosis in patients with multilayer coronary stent restenosis. This development provides a promising alternative to adding extra stent layers, improving treatment outcomes for patients with complex coronary artery disease.